Alatrofloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Alatrofloxacin
Accession Number
DB09335
Type
Small Molecule
Groups
Withdrawn
Description

Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Alatrofloxacin mesylate2IXX802851157605-25-9CYETUYYEVKNSHZ-LGOOQLFJSA-N
Categories
UNII
7QVV6I50DT
CAS number
146961-76-4
Weight
Average: 558.518
Monoisotopic: 558.183852418
Chemical Formula
C26H25F3N6O5
InChI Key
UUZPPAMZDFLUHD-VUJLHGSVSA-N
InChI
InChI=1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1
IUPAC Name
7-[(1R,5S,6S)-6-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
SMILES
[H][[email protected]@]12CN(C[[email protected]]1([H])[[email protected]]2NC(=O)[[email protected]](C)NC(=O)[[email protected]](C)N)C1=NC2=C(C=C1F)C(=O)C(=CN2C1=CC=C(F)C=C1F)C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Alatrofloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Alatrofloxacin.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Alatrofloxacin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alatrofloxacin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Alatrofloxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Alatrofloxacin.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Alatrofloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Alatrofloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Alatrofloxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Alatrofloxacin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alatrofloxacin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Alatrofloxacin.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Alatrofloxacin.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Alatrofloxacin.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Alatrofloxacin.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Alatrofloxacin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alatrofloxacin.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Alatrofloxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Alatrofloxacin.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Alatrofloxacin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
3086677
PubChem Substance
310265213
ChemSpider
21243647
ChEBI
135829
ChEMBL
CHEMBL1201197
Wikipedia
Alatrofloxacin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6080756No1996-07-052016-07-05Us
US6194429No1998-07-232018-07-23Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0388 mg/mLALOGPS
logP0.65ALOGPS
logP-0.83ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)5.41ChemAxon
pKa (Strongest Basic)8.09ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area157.96 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity135.64 m3·mol-1ChemAxon
Polarizability52.84 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Peptides
Alternative Parents
Naphthyridine carboxylic acids and derivatives / Fluoroquinolones / Pyridinecarboxylic acids / Dialkylarylamines / Aminopyridines and derivatives / Fluorobenzenes / Piperidines / Aryl fluorides / Imidolactams / Vinylogous amides
show 14 more
Substituents
Alpha peptide / Naphthyridine carboxylic acid / Fluoroquinolone / Diazanaphthalene / Naphthyridine / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Dialkylarylamine / Aminopyridine / Fluorobenzene
show 34 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on November 26, 2015 16:56 / Updated on November 09, 2017 04:49